Abstract
An elevated pulmonary pressure (PASP >35 mm Hg) is a highly prevalent finding in patients with chronic kidney disease (CKD) – approaching over 30% of patients with CKD in some studies. This is often first detected on an echocardiogram, which is a very common test performed in patients with kidney failure, as the volume overload consistent with CKD can often be confused for congestive heart failure at times. In addition, some national guidelines have recommended a screening echocardiogram at the start of dialysis to rule out possible cardiac contribution to poor kidney function. Often, the high pulmonary pressure is a reflection of chronic volume overload and diastolic dysfunction (WHO group 2 pulmonary HTN), but patients with chronic kidney disease may have other unique factors that make them more susceptible to pulmonary hypertension, including elevated levels of endothelin, decreased levels of nitric oxide, metabolic abnormalities of calcium handling, anemia, and high-flow states associated with an AV fistula. Whether as a marker of underlying disease or as a contributing factor, significant pulmonary hypertension has been associated with worse outcomes in patients with CKD as well as kidney transplant recipients. An invasive hemodynamic study can be used to further classify pulmonary hypertension into sub-groups and help generate targets for optimal treatment. Further work is needed to determine whether some of the advances in the treatment of pulmonary hypertension can help improve clinical outcomes in this challenging group of patients.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Kosmadakis G, Aguilera D, Carceles O, Da Costa CE, Boletis I. Pulmonary hypertension in dialysis patients. Ren Fail. 2013;35(4):514–20.
Shang W, Li Y, Ren Y, Li W, Wei H, Dong J. Prevalence of pulmonary hypertension in patients with chronic kidney disease without dialysis: a meta-analysis. Int Urol Nephrol. 2018;50(8):1497–504.
Workgroup KD. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005;45(4 Suppl 3):S1–153.
Lentine KL, Costa SP, Weir MR, Robb JF, Fleisher LA, Kasiske BL, et al. Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2012;60(5):434–80.
Bolignano D, Pisano A, Coppolino G, Tripepi GL, D’Arrigo G. Pulmonary hypertension predicts adverse outcomes in renal patients: a systematic review and meta-analysis. Ther Apher Dial. 2018;23:369.
Zlotnick DM, Axelrod DA, Chobanian MC, Friedman S, Brown J, Catherwood E, et al. Non-invasive detection of pulmonary hypertension prior to renal transplantation is a predictor of increased risk for early graft dysfunction. Nephrol Dial Transplant. 2010;25(9):3090–6.
Issa N, Krowka MJ, Griffin MD, Hickson LJ, Stegall MD, Cosio FG. Pulmonary hypertension is associated with reduced patient survival after kidney transplantation. Transplantation. 2008;86(10):1384–8.
Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010;23(7):685–713; quiz 86-8.
McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53(17):1573–619.
O’Leary JM, Assad TR, Xu M, Birdwell KA, Farber-Eger E, Wells QS, et al. Pulmonary hypertension in patients with chronic kidney disease: invasive hemodynamic etiology and outcomes. Pulm Circ. 2017;7(3):674–83.
Di Lullo L, Gorini A, Russo D, Santoboni A, Ronco C. Left ventricular hypertrophy in chronic kidney disease patients: from pathophysiology to treatment. Cardiorenal Med. 2015;5(4):254–66.
Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29(4):277–314.
Nakhoul F, Yigla M, Gilman R, Reisner SA, Abassi Z. The pathogenesis of pulmonary hypertension in haemodialysis patients via arterio-venous access. Nephrol Dial Transplant. 2005;20(8):1686–92.
Akmal M, Barndt RR, Ansari AN, Mohler JG, Massry SG. Excess PTH in CRF induces pulmonary calcification, pulmonary hypertension and right ventricular hypertrophy. Kidney Int. 1995;47(1):158–63.
Yigla M, Nakhoul F, Sabag A, Tov N, Gorevich B, Abassi Z, et al. Pulmonary hypertension in patients with end-stage renal disease. Chest. 2003;123(5):1577–82.
Lentine KL, Villines TC, Axelrod D, Kaviratne S, Weir MR, Costa SP. Evaluation and management of pulmonary hypertension in kidney transplant candidates and recipients: concepts and controversies. Transplantation. 2017;101(1):166–81.
Wattanakit K, Cushman M. Chronic kidney disease and venous thromboembolism: epidemiology and mechanisms. Curr Opin Pulm Med. 2009;15(5):408–12.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Costa, S.P. (2020). Pulmonary Hypertension in Chronic Kidney Disease. In: Rangaswami, J., Lerma, E., McCullough, P. (eds) Kidney Disease in the Cardiac Catheterization Laboratory . Springer, Cham. https://doi.org/10.1007/978-3-030-45414-2_24
Download citation
DOI: https://doi.org/10.1007/978-3-030-45414-2_24
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-45413-5
Online ISBN: 978-3-030-45414-2
eBook Packages: MedicineMedicine (R0)